

From: [REDACTED]
To: [ETF SMB Board Feedback](#)
Subject: Adding anti-obesity medications to the State of Wisconsin Group Health Insurance Program
Date: Thursday, April 27, 2023 10:16:44 AM
Attachments: [4.20.23 AOM Carla Buchanan.docx](#)

**CAUTION: This email originated from outside the organization.
Do not click links or open attachments unless you recognize the sender and know the content is safe.**

Hello,

As a retired public employee with Rock County Child Support Agency, I am writing to you regarding the consideration for anti-obesity medications (AOMs) to be added to the State of Wisconsin Group Health Insurance Program so public employees have equitable access to the care we need. Healthcare providers have endorsed these medications as a way to treat obesity without surgery or surgical aftercare. As part of a chronic weight loss or management program, these medicines have proved to increase an individual's weight loss over time and have allowed individuals to decrease or even cease the use of other medications they have to use to combat the side effects of chronic obesity. Adding AOMs to the health insurance program for public employees can lead to numerous benefits, such as improved health outcomes and quality of life for members, increased productivity, etc.

As state employees in Wisconsin, we deserve to have access to the same quality of care our peers have in all of our neighboring states. Minnesota, Iowa, Illinois, Indiana, and Michigan have already taken the crucial step in ensuring their public employees have access to AOMs, and many private sector employees have access to these treatments as well.

Wisconsin public employees will not only have access to the same care as other states; we can also be competitive in productivity and employee satisfaction. Including AOMs in the state employee health insurance plan can bring us up to speed with our peers and aid in productivity at work. If members have access to AOMs in their health insurance plan, individuals may be able to improve their energy levels, reduce absenteeism, and increase productivity at work.

The Wisconsin Medicaid program offers anti-obesity medication as a benefit to their recipients. Allowing these medications with prior authorization to be covered by ETF medical insurance plans not only provides an affordable, convenient option for individuals needing to lose weight and manage their chronic disease but also would show members that the State of Wisconsin benefit plans meet their employee needs. I am also asking the GIB to add AOMs to the State of Wisconsin Group Health Insurance Program. Thank you for your consideration on this matter and for allowing me to advocate as an employee on this issue.

Sincerely,
Carla Buchanan

April 20, 2023

TO: The Group Insurance Board (GIB) ETFSMBBoardFeedback@etf.wi.gov

FROM: Carla Buchanan, Retiree, Rock County Child Support Agency

RE: Adding anti-obesity medications to the State of Wisconsin Group Health Insurance Program

Hello,

As a retired public employee with Rock County Child Support Agency, I am writing to you regarding the consideration for anti-obesity medications (AOMs) to be added to the State of Wisconsin Group Health Insurance Program so public employees have equitable access to the care we need. Healthcare providers have endorsed these medications as a way to treat obesity without surgery or surgical aftercare. As part of a chronic weight loss or management program, these medicines have proved to increase an individual's weight loss over time and have allowed individuals to decrease or even cease the use of other medications they have to use to combat the side effects of chronic obesity. Adding AOMs to the health insurance program for public employees can lead to numerous benefits, such as improved health outcomes and quality of life for members, increased productivity, etc.

As state employees in Wisconsin, we deserve to have access to the same quality of care our peers have in all of our neighboring states. Minnesota, Iowa, Illinois, Indiana, and Michigan have already taken the crucial step in ensuring their public employees have access to AOMs, and many private sector employees have access to these treatments as well.

Wisconsin public employees will not only have access to the same care as other states; we can also be competitive in productivity and employee satisfaction. Including AOMs in the state employee health insurance plan can bring us up to speed with our peers and aid in productivity at work. If members have access to AOMs in their health insurance plan, individuals may be able to improve their energy levels, reduce absenteeism, and increase productivity at work.

The Wisconsin Medicaid program offers anti-obesity medication as a benefit to their recipients. Allowing these medications with prior authorization to be covered by ETF medical insurance plans not only provides an affordable, convenient option for individuals needing to lose weight and manage their chronic disease but also would show members that the State of Wisconsin benefit plans meet their employee needs. I am also asking the GIB to add AOMs to the State of Wisconsin Group Health Insurance Program. Thank you for your consideration on this matter and for allowing me to advocate as an employee on this issue.

Sincerely,
Carla Buchanan



STATE OF WISCONSIN
Department of Employee Trust Funds
A. John Voelker
SECRETARY

Wisconsin Department
of Employee Trust Funds
PO Box 7931
Madison WI 53707-7931
1-877-533-5020 (toll free)
Fax 608-267-4549
etf.wi.gov

April 28, 2023

Carla Buchanan
[REDACTED]

Dear Carla Buchanan:

Thank you for your email to the Group Insurance Board (Board) regarding adding coverage of anti-obesity medications (AOMs) to the Group Health Insurance Program (GHIP).

You are correct that AOMs currently are not covered under the GHIP. However, the Board has discussed adding AOMs to the pharmacy formulary in the past. The Board faces limitations on adding coverage for benefits that are not mandated by law unless savings can be demonstrated, or benefits are reduced (see [Wis. Stat. § 40.03\(6\)\(c\)](#)). The Board reviewed coverage of AOMs through the pharmacy benefit at the June 30, 2022, meeting. As noted in the ["Weight-Loss Drug Coverage Options Review"](#) memo, the Board's actuary, Segal, estimated the cost of adding weight-loss drugs to the Board's non-Medicare formulary would be between \$12 million–\$17 million per year, or about \$11,000 to \$13,000 per person. The most recently available studies produced on these drugs report they are only estimated to save about \$1,400 per person who takes the drug per year. This was one of the reasons the Board was not able to add coverage.

Another reason the Board is hesitant to add coverage is uncertainty about the long-term effects of these drugs. AOM drug manufacturers have conducted studies of the short-term effects of taking AOMs for up to 72 weeks. However, most research indicates that people will be on AOMs for multiple years and, in some cases, possibly the rest of their lives. Long-term studies of AOMs aim to answer the questions of whether weight regain may occur over time despite continued therapy, whether maintaining weight loss is viable under the drug, and the good and bad health effects of taking weight-loss drugs for a long duration. The timelines and release dates of the information from these ongoing studies are unknown.

In your email, you observed that some state employees in neighboring states do have coverage of AOMs, which is correct. However, that coverage varies, and often other requirements must be met. For example, a Minnesota State employee must pay the full cost of AOMs for three months and lose five percent of their body weight before the Minnesota State pharmacy benefit would start to pay for the AOM. These requirements

Carla Buchanan

April 28, 2023

Page 2

significantly limit the number of Minnesota State Employees who take weight-loss drugs.

In your email, you mentioned that the Wisconsin Medicaid program offers AOMs as a benefit to their recipients. According to the [“Medicaid Best Price”](#) article, published in 2017 in *Health Affairs* journal and written by Ramsey Baghdadi, Medicaid’s best price policy mandates that a drug manufacturer must offer state Medicaid Programs the best price given to any other purchaser with a mandatory rebate of 23.1% off the list price of the drug. Currently, only Medicaid programs can achieve this level of rebates and thereby realize some price reduction on AOMs.

People on Medicare cannot receive AOMs through their Medicare Part D coverage.⁴² [U.S.C. § 1395W-102](#) prevents the Centers for Medicare & Medicaid, which creates the Medicare Part D formulary, from including coverage for AOMs.

GHIP members can obtain some AOMs, such as Wegovy and Saxenda, at a discounted rate. The drugs on the attached “Department of Employee Trust Funds Discount Drug List” are not covered by the GHIP’s pharmacy benefit but can be obtained at the negotiated rate Navitus Health Solutions, the Board’s Pharmacy Benefit Manager (PBM), has with the pharmacy filling the drug prescription. The pharmacy-negotiated rate will be lower than the full price of the drug. Please note that the price a member pays will not count towards any out-of-pocket limits (OOPL) or any pharmacy deductible.

During the February 22, 2023, Board meeting, the Board received a [“2024 Preliminary Agreement and Benefit Changes”](#) memo and presentation regarding possible health insurance and pharmacy benefit changes for 2024. Coverage of weight-loss drugs is discussed in that memo.

At the upcoming May 17, 2023, Board meeting, ETF staff will present the Board with their findings regarding preliminary changes, including the addition of weight-loss drug coverage for 2024. The May meeting agenda, Board memos, and other materials will be posted to the ETF website on the [“Group Insurance Board Meeting Agendas and Materials”](#) page before the meeting.

Again, thank you for your email. If you have any other questions, comments, or concerns, please do not hesitate to contact me using the information below.

Sincerely,

Tricia Sieg, Pharmacy Benefits Program Manager
Office of Strategic Health Policy
Department of Employee Trust Funds
tricia.sieg@etf.wi.gov
608-261-6006

Department of Employee Trust Funds Discount Drug List

Updated January 2023

Prescriptions that are not covered by your pharmacy benefit may be available at a discounted rate. This may include drugs for infertility, weight loss, cosmetic or other lifestyle needs as prescribed by your doctor. You can use your Health Care Flexible Spending account to pay for them, with a prescription.

DRUG	Copay	Drug Category
ADIPEX-P CAP	100%	WEIGHT LOSS
ADIPEX-P TAB	100%	WEIGHT LOSS
AVAGE CREAM	100%	COSMETICS
CAVERJECT INJ	100%	INJECTABLES, SEXUAL DYSFUNCTION
cetorelix acetate for inj kit	100%	INFERTILITY, INJECTABLES
CETROTIDE INJ KIT	100%	INFERTILITY, INJECTABLES
CHROMELIN SOLN	100%	COSMETICS
CLOMID TAB, CLOMIPHENE CITRATE TAB	100%	INFERTILITY
CLOMIPHENE CITRATE POWDER	100%	INFERTILITY
CONTRACE TAB	100%	WEIGHT LOSS
DY-O-DERM SOLN	100%	COSMETICS
EDEX INJ	100%	INJECTABLES, SEXUAL DYSFUNCTION
finasteride tab	100%	COSMETICS
FOLLISTIM AQ INJ	100%	INFERTILITY, INJECTABLES
ganirelix ac inj	100%	INFERTILITY, INJECTABLES
GONAL-F RFF INJ	100%	INFERTILITY, INJECTABLES
hydroquinone cream	100%	COSMETICS
leuprolide inj	100%	INFERTILITY, INJECTABLES
LUPRON DEPOT INJ	100%	INJECTABLES
LUSTRA CREAM	100%	COSMETICS
MENOPUR INJ	100%	INFERTILITY, INJECTABLES
METHOXSALEN POWDER	100%	COSMETICS
minoxidil soln	100%	COSMETICS
MUSE SUPP	100%	SEXUAL DYSFUNCTION
OVIDREL INJ	100%	INFERTILITY, INJECTABLES
PAPAVERINE/ALPROSTADIL INJ	100%	INJECTABLES, SEXUAL DYSFUNCTION
PAPAVERINE/PHENTOLAMINE INJ	100%	INJECTABLES, SEXUAL DYSFUNCTION
PAPAVERINE/PHENTOLAMINE/ALPROSTADIL INJ	100%	INJECTABLES, SEXUAL DYSFUNCTION
phentermine cap	100%	WEIGHT LOSS
phentermine tab	100%	WEIGHT LOSS
PHENTOLAMINE/ALPROSTADIL INJ	100%	INJECTABLES, SEXUAL DYSFUNCTION
PREGNYL INJ	100%	INFERTILITY

PROPECIA TAB	100%	COSMETICS
QSYMIA CAP	100%	WEIGHT LOSS
RENOVA CREAM	100%	COSMETICS
ROGAINE SOLN	100%	COSMETICS
SAXENDA INJ	100%	INJECTABLES, WEIGHT LOSS
sildenafil tab	100%	SEXUAL DYSFUNCTION
STENDRA	100%	SEXUAL DYSFUNCTION
tadalafil tab	100%	SEXUAL DYSFUNCTION
TRELSTAR INJ	100%	INFERTILITY, INJECTABLES
TRI-LUMA CREAM	100%	COSMETICS
VANIQA CREAM	100%	COSMETICS
varденаfil ODT	100%	SEXUAL DYSFUNCTION
varденаfil tab	100%	SEXUAL DYSFUNCTION
VITADYE LOTION	100%	COSMETICS
WEGOVY INJ	100%	INJECTABLES, WEIGHT LOSS
WEGOVY INJ 1.7MG/0.75ML	100%	INJECTABLES, WEIGHT LOSS
WEGOVY INJ 2.4MG/0.75ML	100%	INJECTABLES, WEIGHT LOSS
XENICAL CAP	100%	WEIGHT LOSS